How to buy NuCana stock | $3.06

NuCana plc is a biotechnology business based in the US. NuCana shares (NCNA) are listed on the NASDAQ and all prices are listed in US Dollars. NuCana employs 27 staff and has a market cap (total outstanding shares value) of 0.00.

NuCana stock price (NASDAQ: NCNA)

Use our graph to track the performance of NCNA stocks over time.

NuCana shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$3.06
52-week range	$2.03 - $7.77
50-day moving average	$2.64
200-day moving average	$4.23
Wall St. target price	$1,144.93
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.63

Buy NuCana shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NuCana stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NuCana plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NuCana price performance over time

Historical closes compared with the close of $3.06 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	8.90%
3 months (2021-05-04)	-23.31%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

NuCana financials

Gross profit TTM	$0
Return on assets TTM	-26.97%
Return on equity TTM	-48.03%
Profit margin	0%
Book value	$1.77
Market capitalisation	$109.9 million

TTM: trailing 12 months

Shorting NuCana shares

There are currently 798,313 NuCana shares held short by investors – that's known as NuCana's "short interest". This figure is 61% up from 495,942 last month.

There are a few different ways that this level of interest in shorting NuCana shares can be evaluated.

NuCana's "short interest ratio" (SIR)

NuCana's "short interest ratio" (SIR) is the quantity of NuCana shares currently shorted divided by the average quantity of NuCana shares traded daily (recently around 528684.10596026). NuCana's SIR currently stands at 1.51. In other words for every 100,000 NuCana shares traded daily on the market, roughly 1510 shares are currently held short.

However NuCana's short interest can also be evaluated against the total number of NuCana shares, or, against the total number of tradable NuCana shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NuCana's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 NuCana shares in existence, roughly 20 shares are currently held short) or 0.0253% of the tradable shares (for every 100,000 tradable NuCana shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NuCana.

Find out more about how you can short NuCana stock.

NuCana share dividends

We're not expecting NuCana to pay a dividend over the next 12 months.

NuCana share price volatility

Over the last 12 months, NuCana's shares have ranged in value from as little as $2.03 up to $7.77. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuCana's is 0.766. This would suggest that NuCana's shares are less volatile than average (for this exchange).

NuCana overview

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.

Frequently asked questions

What percentage of NuCana is owned by insiders or institutions?
Currently 0.409% of NuCana shares are held by insiders and 54.609% by institutions. How many people work for NuCana?
Latest data suggests 27 work at NuCana. When does the fiscal year end for NuCana?
NuCana's fiscal year ends in December. Where is NuCana based?
NuCana's address is: 3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT What is NuCana's ISIN number?
NuCana's international securities identification number is: US67022C1062 What is NuCana's CUSIP number?
NuCana's Committee on Uniform Securities Identification Procedures number is: 67022C106